BTIG analyst Ryan Zimmerman raised the firm’s price target on OrthoPediatrics (KIDS) to $24 from $23 and keeps a Buy rating on the shares. The company is making steady progress against profitability targets, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics Highlights Growth Strategy in 2026 Investor Presentation
- OrthoPediatrics announces iotaMotion received FDA 510k clearance for iotaSOFT
- OrthoPediatrics initiated with a Buy at TD Cowen
- OrthoPediatrics (KIDS): Pediatric Ortho Leader in an Underpenetrated Market with Improving Profitability and Valuation Upside
- OrthoPediatrics: Strengthening Fundamentals, Sustained Double-Digit Growth, and Improving Cash Generation Support Buy Rating